Loncar Cancer Immunotherapy ETF (CNCR)

NASDAQ: CNCR · IEX Real-Time Price · USD
15.67
+0.23 (1.50%)
At close: Jun 24, 2022 4:00 PM
15.67
0.00 (0.00%)
After-hours: Jun 24, 2022 4:15 PM EDT
1.50%
Assets $22.72M
NAV $15.67
Expense Ratio 0.79%
PE Ratio n/a
Shares Out 1.45M
Dividend (ttm) $1.85
Dividend Yield 11.83%
Ex-Dividend Date Dec 29, 2021
1-Year Return -51.12%
Volume 7,612
Open 15.86
Previous Close 15.44
Day's Range 15.39 - 15.86
52-Week Low 12.76
52-Week High 32.99
Beta 1.05
Holdings 31
Inception Date Oct 13, 2015

About CNCR

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.

Asset Class Equity
Sector Biotech
Region Global
Issuer Exchange Traded Concepts
Stock Exchange NASDAQ
Ticker Symbol CNCR
Index Tracked Loncar Cancer Immunotherapy Index

Top 10 Holdings

37.32% of assets
Name Symbol Weight
Lyell Immunopharma LYEL 4.18%
IGM Biosciences IGMS 3.86%
Fate Therapeutics FATE 3.84%
Allogene Therapeutics ALLO 3.68%
Iovance Biotherapeutics IOVA 3.66%
Replimune Group REPL 3.65%
Xencor XNCR 3.64%
Immunocore Holdings IMCR 3.62%
Nektar Therapeutics NKTR 3.60%
I-Mab IMAB 3.58%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 29, 2021 $1.8533352 Dec 31, 2021
Dec 30, 2020 $0.2881193 Jan 4, 2021
Dec 28, 2017 $0.35019938 Jan 2, 2018
Dec 29, 2015 $0.10551286 Jan 4, 2016
Full Dividend History

News

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

Other symbols: BBCPFESBIOXBI

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

Other symbols: BBCBNTXCEREIEIHPFE

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Here is what you should know about investing in these life changing technologies.

Biotech ETFs extend January gains

Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-mor...

Other symbols: GERMXBI

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

As U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to Rally

Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...

Other symbols: IBBXBI

Biotech ETFs Remain Hot As Investors Await Upcoming Vaccine

Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...

Other symbols: BBHIBB

Will Moderna Vaccine News Boost Biotech ETFs?

Monday saw stocks and index ETFs surge, after the announcement from Pfizer that the pharmaceutical giant had a vaccine candidate with an over 90% effectiveness in clinical trials. Now another biotech, M...

Other symbols: BBHIBB

7 Top ETFs That Trumped Last Week's Market Rout

Last week was extremely volatile for Wall Street with the S&P 500, the Dow Jones and the Nasdaq losing about 2.5%, 1.7% and 4.1%, respectively.

Other symbols: DWSHEPHEITB

6 Sector ETFs Surviving the Market Rout

Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.

Other symbols: AZNGERMITBMXIRINGTAN

5 ETFs Jump After Three-Day Rout: Will The Rally Last?

We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.

Other symbols: ARKQPBWPTH

Specialty biotech funds jump on promising coronavirus, funding news

Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. The ...

Other symbols: PTH

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

Other symbols: BBHBTECGERMIBBIDNAXBI

Moderna Vaccine Optimism Could Drive Biotech ETFs

Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creatin...

Other symbols: BBHIBBXBI

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

Other symbols: BTECGERMIBBPBEXBI

7 Biotech ETFs to Buy Now For Covid-19 And Beyond

Biotech ETFs are popular and delivering for investors, but not all of these funds need the Covid-19 pandemic to soar.

Other symbols: ARKGBTECFBTGERMSBIOXBI

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Moderna Study Sends Biotech ETFs And Stock Futures Surging

Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...

Other symbols: BBHBTECIBBXBI

7 ETFs for the End of the Coronavirus

The Covid-19 pandemic dinged a slew of asset classes, but these ETFs are positioned to benefit when the virus is squashed.

Other symbols: ARKFAWAYBJKEWZJETSXLI

AstraZeneca Joins Coronavirus Vaccine Race, Great For Biotech ETFs

With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.

Other symbols: AZNBBHIBBXBI

3 ETFs For More Moderna Bets

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

Other symbols: BTECIDNA

Biotech ETFs Climbing As Moderna Builds Hope For Coronavirus Vaccine

U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...

Other symbols: IBBXBI

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Other symbols: IBBPBEXBI

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.